501-75-7

Basic information

• Product Name: 2-(1-methylimidazol-4-yl)ethanamine
• Synonyms: 2-(1-methylimidazol-4-yl)ethanamine;tele-methylhistamine;1-Methyl-1H-imidazole-4-ethanamine;4-(2-Aminoethyl)-1-methyl-1H-imidazole;N1-Methylhistamine;1-methyl-4-(2-aminoethyl)imidazole;4-(1-aminoethyl)-1-methyl-1H-imidazole;N(T)-methylhistamine
• CAS NO: 501-75-7
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.1716
• Mol File: 501-75-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 296.7 °C at 760 mmHg
• Flash Point: 133.2 °C
• Appearance: /
• Density: 1.11 g/cm³
• PKA: 9.27±0.10(Predicted)
• CAS DataBase Reference: 2-(1-methylimidazol-4-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-methylimidazol-4-yl)ethanamine(501-75-7)
• EPA Substance Registry System: 2-(1-methylimidazol-4-yl)ethanamine(501-75-7)

Safety Data

• Hazardous Substances Data: 501-75-7(Hazardous Substances Data)

Usage

Description

2-(1-methylimidazol-4-yl)ethanamine, also known as 2-(1-methyl-1H-imidazol-4-yl)ethan-1-amine, is a primary amino compound that is the Ntau-methyl derivative of histamine. It is characterized by its unique chemical structure, which includes an imidazole ring and an ethanamine group.

Uses

Used in Nutritional Supplements:
2-(1-methylimidazol-4-yl)ethanamine is used as a nutritional supplement in high fiber diets. It plays a role in promoting gluconeogenesis, which is the process of producing glucose from non-carbohydrate sources, and inhibiting glycolysis in muscle, which is the breakdown of glucose to release energy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(1-methylimidazol-4-yl)ethanamine may be utilized for its potential therapeutic applications due to its histamine-like structure. This could include the development of drugs targeting various conditions where histamine plays a role, such as allergies or certain neurological disorders.
Used in Research and Development:
2-(1-methylimidazol-4-yl)ethanamine can also be used as a research compound in the development of new drugs and therapies. Its unique chemical structure may provide insights into the design of novel molecules with specific biological activities.

Upstream product

• 41065-00-3 1-Methyl-4-cyanomethyl-imidazol 
• 673-49-4 N-acetylhistamine 
• 77-78-1 dimethyl sulfate 
• 51720-37-7 2-methyl-5-oxo-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidinium iodide 
• 51-45-6 histamine 
• 14509-66-1 5,6,7,8-tetrahydro-5-oxoimidazo[1,5-c]pyrimidine 
• 51-45-6 histamine 
• 18502-05-1 4-cyanomethylimidazole 

Downstream Products

• 64403-25-4 3-methyl-3,4,6,7-tetrahydro-5H-imidazo<4,5-c>pyridine 
• 58177-25-6 4-hydroxyethyl-1-methyl-1H-imidazole 
• 210238-13-4 (2R,3R,4S,5R)-2-{6-Benzylamino-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-69-0 (2R,3R,4S,5R)-2-{6-Benzylamino-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-isopropyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-07-6 (2R,3R,4S,5R)-2-{6-(2,2-Diphenyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-21-4 (2R,3R,4S,5R)-2-{2-[2-(1-Methyl-1H-imidazol-4-yl)-ethylamino]-6-phenethylamino-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-15-6 (2R,3R,4S,5R)-2-{6-(2-Cyclohexyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-11-2 (2R,3R,4S,5R)-2-{6-(3-Iodo-benzylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 1225591-15-0 1-[(R)-2-(4-butyryl-4-cyclohexylpiperidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]-3-[2-(1-methyl-1H-imidazol-4-yl)ethyl]urea 
• 1419868-80-6 C₃₁H₃₅N₇O₃ 

Relevant articles and documents

-

-

2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl)ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R poten

CXCR4 chemokine receptor binding comounds

The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.